登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C16H16N5NaO7S2
化学文摘社编号:
分子量:
477.45
UNSPSC Code:
51284136
NACRES:
NA.85
PubChem Substance ID:
EC Number:
264-915-9
Beilstein/REAXYS Number:
5711411
MDL number:
产品名称
Cefotaxime sodium salt 钠盐, potency: 916-964 μg per mg
form
powder
SMILES string
[Na+].[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c3csc(N)n3)C([O-])=O
InChI
1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1
InChI key
AZZMGZXNTDTSME-JUZDKLSSSA-M
potency
916-964 μg per mg
solubility
H2O: 50 mg/mL
antibiotic activity spectrum
Gram-negative bacteria
Gram-positive bacteria
mode of action
cell wall synthesis | interferes
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Mode of Action: Inhibits bacterial cell wall synthesis.
Cefotaxim inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. As a result, bacteria lyse due to cell wall autolytic enzymes.
Other Notes
Broad spectrum third generation cephalosporin antibiotic.
Keep container tightly closed in a dry and well-ventilated place.
Application
Cefotaxim has been used to find new residues involved in cefotaxime hydrolysis in CTX-M β-lactamases, to study antibiotic-susceptible and -resistant Streptococcus pneumoniae infections, and to study pneumococcal pneumonia and the pharmokinetics of various treatments. It may be used to study the effects of binding and inhibition of penicillin binding protein 2 (PBP2) on bacterial mucopeptide synthesis.
General description
Chemical structure: ß-lactam
signalword
Danger
hcodes
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
涉药品监管产品
此项目有
Violeta Rodríguez-Cerrato et al.
The Journal of antimicrobial chemotherapy, 60(5), 1159-1162 (2007-09-11)
In an innovative therapeutic exploitation against antibiotic-resistant Streptococcus pneumoniae, here we have evaluated the in vitro activity of a purified bacterially-encoded cell wall lytic enzyme, LytA (the major pneumococcal autolysin), and compared it with those of Cpl-1 and Pal (pneumococcal
Francisco José Pérez-Llarena et al.
Antimicrobial agents and chemotherapy, 55(9), 4361-4368 (2011-07-07)
The CTX-M β-lactamases are an increasingly prevalent group of extended-spectrum β-lactamases (ESBL). Point mutations in CTX-M β-lactamases are considered critical for enhanced hydrolysis of cefotaxime. In order to clarify the structural determinants of the activity against cefotaxime in CTX-M β-lactamases
F Soriano et al.
The Journal of antimicrobial chemotherapy, 38(2), 227-236 (1996-08-01)
In an attempt to determine the susceptibility breakpoints for amoxycillin, co-amoxiclav and cefotaxime in pneumococcal pneumonia, a neutropenic mouse model was established and tested with two strains having different susceptibility to penicillins and cefotaxime. With a penicillin-sensitive strain (MIC/MBC =
Martijn F Schenk et al.
PLoS genetics, 8(6), e1002783-e1002783 (2012-07-05)
For a quantitative understanding of the process of adaptation, we need to understand its "raw material," that is, the frequency and fitness effects of beneficial mutations. At present, most empirical evidence suggests an exponential distribution of fitness effects of beneficial
Katrine Hartung Hansen et al.
Applied and environmental microbiology, 79(3), 794-798 (2012-11-20)
Current knowledge on extended-spectrum beta-lactamases (ESBLs) in animals is based largely on cross-sectional studies and qualitative data. The aim of this longitudinal study was to elucidate carriage proportions and fecal counts of ESBL-producing Escherichia coli in pigs during the production
相关内容
Product Information Sheet
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持